Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $274.5 million in Q3 2025.

• For the quarter ending Q3 2025, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million; the trailing twelve-month figure through Sep 2025 stood at $314.9 million (up 49.19% YoY), and the FY2024 full-year result was $255.6 million, up 91.37% from the prior year.
• Cash from Financing Activities for Q3 2025 stood at $274.5 million, up from $568000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $274.5 million in Q3 2025, with the low at -$4.9 million in Q4 2023.
• Average Cash from Financing Activities over 5 years is $56.7 million, with a median of $418000.0 recorded in 2021.
• Year-over-year, Cash from Financing Activities plunged 99.94% in 2022 and jumped 92640.88% in 2025.
• Tracing DNTH's Cash from Financing Activities over 5 years: stood at $124000.0 in 2021, then surged by 77825.0% to $96.6 million in 2022, then slumped by 105.03% to -$4.9 million in 2023, then jumped by 915.54% to $39.7 million in 2024, then surged by 591.89% to $274.5 million in 2025.
• The last three Cash from Financing Activities figures came in at $274.5 million (Q3 2025), $568000.0 (Q2 2025), and $161000.0 (Q1 2025), per Business Quant data.

Peer Comparison